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Multiple myeloma (MM) is a clinically and genetically heterogeneous malignant proliferation of plasma cells 
(PCs) with a typical multifocal distribution in the bone marrow (BM) and occasional extra-medullary 
dissemination.1 Advances in the genetic knowledge of MM are increasingly translated into biomarkers to 
refine diagnosis, prognostication and treatment of patients.2 
MM genotyping has so far relied on the analysis of purified PCs from the bone marrow (BM) aspirate, which 
may fail in capturing the postulated spatial heterogeneity of the disease and imposes technical hurdles 
limiting its transfer in the routine and clinical grade diagnostic laboratory. In addition, longitudinal monitoring 
of disease molecular markers may be limited by patient discomfort caused by repeated BM samplings during 
disease course. Circulating tumor DNA is shed into the peripheral blood (PB) by tumor cells and can be used 
as source of tumor DNA for the identification of cancer-gene somatic mutations, with obvious advantages in 
terms of accessibility. In addition, the systemic origin of cell-free DNA (cfDNA) allows catching the entire 
tumor heterogeneity.3 Tumor cfDNA was identified in MM patients by preliminary studies tracking the 
clonotypic V(D)J rearrangement as disease fingerprint,4 or genotyping a highly restricted set of cancer genes 
that were not specifically addressed to resolve the typical MM mutational landscape.5-7 We developed a 
CAPP-seq ultra-deep targeted next-generation sequencing (NGS) approach to genotype a gene panel 
specifically designed to maximize the mutation recovery in plasma cell tumors, and compared the mutational 
profiling of cfDNA and tumor genomic DNA (gDNA) of purified PCs from BM aspirates in a consecutive 
series of patients representative of different clinical stages of PC tumors ranging from monoclonal 
gammopathy of undetermined significance (MGUS), to smoldering MM, and symptomatic MM. 
The study was based on a series of 28 patients with PC disorders, whose clinical and molecular 
characteristics were consistent with an unselected cohort of PC dyscrasia patients (Supplementary Table 
S1) [two had MGUS, five smoldering MM (SMM), and 21 symptomatic MM]. The study was conducted 
according to good clinical practice and the ethical principles outlined in the Declaration of Helsinki. All 
patients provided written informed consent. The following material was collected: cfDNA isolated from 
plasma; tumor gDNA from CD138+ purified BM PCs for comparative purposes, and germline gDNA 
extracted from PB granulocytes after Ficoll gradient separation, to filter out polymorphisms. The sampling 
was done in 25 newly diagnosed and three relapsed/refractory treated patients. A targeted resequencing 
gene panel, including coding exons and splice sites of 14 genes (target region: 31 kb: BRAF, CCND1, CYLD, 
DIS3, EGR1, FAM46C, IRF4, KRAS, NRAS, PRDM1, SP140, TP53, TRAF3, ZNF462; Supplementary Table 
S2) was specifically designed and optimized to allow a priori the recovery of at least one mutation in 68% 
(95% confidence interval: 58-76%) of patients, based on literature data.8-10 Ultra-deep NGS was performed 
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on MiSeq (Illumina) using the CAPP-seq library preparation strategy (NimbleGen).11 The somatic function of 
VarScan2 was used to call non-synonymous somatic mutations, and a stringent bioinformatic pipeline was 
developed and applied to filter out sequencing errors (detection limit 3x10-3). The sensitivity and specificity of 
plasma cfDNA genotyping were calculated in comparison with tumor gDNA genotyping as the gold standard. 
Details of the experimental procedures are given in the Supplementary Methods. 
cfDNA was detectable in plasma samples with an average of ∼11 000 haploid genome-equivalents per 
mL of plasma (range: 19-52562 hGE/mL; median: 6617 hGE/mL). The amount of cfDNA correlated with 
clinic-pathological parameters reflecting tumor load/extension, including BM PC infiltration (Spearman’s rho 
coefficient=0.42, P=0.02; Supplementary Figure S1A), and clinical stage. Indeed patients presenting with 
ISS stage 3 had significantly higher amounts of cfDNA compared with MGUS/SMM samples and MM cases 
at ISS stages 1-2 (P=0.01; Supplementary Figure S1B, Mann-Whitney test). Conversely, we did not observe 
differences in cfDNA concentration between newly diagnosed and relapsed/refractory MM patients (data not 
shown). More than 90% of the target region was covered  1000X in all plasma samples, and  2000X in 
23/28 (Supplementary Figure S2 and Supplementary Table S3). Overall, within the interrogated genes, 
18/28 (64%) patients had at least one non-synonymous somatic mutation detectable in cfDNA (Figure 1A 
and Table 1A); 28 total variants were identified, with a range of 1-4 mutations per patient. Quite consistent 
with the typical spectrum of mutated genes in MM, plasma cfDNA genotyping revealed somatic variants of 
NRAS in 25%; KRAS in 14%; TP53, TRAF3 and FAM46C in 11%, respectively, CYLD and DIS3 in 7%, 
respectively, and BRAF and IRF4 in 4% of cases, respectively. Variants in NRAS, KRAS and BRAF genes 
occurred in a mutually exclusive manner, and they overall involved 43% of patients. TP53 mutations were 
positively associated with the deletion of the remaining allele as revealed by fluorescence in situ 
hybridization on purified PCs (P=0.02, Fisher-exact test). Overall, the molecular spectrum of mutations 
discovered in tumor cfDNA reflected previous observations in genomic studies based on PC genotyping (see 
representative example for the two most frequently mutated genes in Supplementary Figure S3), thus 
supporting the tumor origin of the mutations identified in cfDNA. 
To validate the tumor origin of mutations discovered in cfDNA and to derive the accuracy of our 
approach in resolving tumor genetics, the genotype of cfDNA was matched with that of gDNA from purified 
BM PCs in all the patients. Sequencing of tumor gDNA identified 39 somatic mutations in 20/28 (71.4%) 
patients (Figure 1A). cfDNA genotyping correctly identified 72% of mutations (n=28/39) that were discovered 
in tumor PCs (Supplementary Figure S4A); overall the variant allele frequencies in plasma samples 
correlated with those in tumor biopsies (Pearson correlation coefficient=0.58, P=9.6e-05; Supplementary 
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Figure S4B) and with the degree of bone marrow involvement (Pearson correlation coefficient=0.5, 
P=0.006). Specifically, of the 28 mutations correctly identified in tumor cfDNA, four were detected in two 
SMM patients out of a total of 7 biopsy-confirmed mutations (4/7, 57%) in three SMM patients, and 24 were 
detected in 16 MM cases out of a total of 32 biopsy-confirmed mutations (24/32, 75%) in 17 MM cases. 
Notably, BM PC confirmed mutations not discovered in cfDNA (n=11) had a low representation in the tumor 
(median allelic frequency: 2.5%; range: 1.1-4.96%) (Table 1B, Figure 1B). Since circulating tumor DNA is 
diluted in cfDNA from normal cells,12, 13 variants that are already rare in tumor gDNA are much less 
represented in plasma and may fall below the sensitivity threshold of the CAPP-seq under the experimental 
conditions adopted in this work. Consistently, based on ROC analysis, cfDNA genotyping has the best 
performance in detecting tumor PC confirmed mutations when they are represented in at least 5% of the 
alleles of tumor plasma cells (Supplementary Figure S4C). Above this threshold, cfDNA genotyping detected 
100% of biopsy-confirmed mutations. Noteworthy, cfDNA genotyping was still able to detect almost half 
(10/21) of low-abundance mutations in tumor PC (i.e. allelic frequency <20%), indicating a good capacity of 
tumor cfDNA to mirror also the subclonal composition of the tumor. Of course, these data concerning the 
sensitivity of cfDNA genotyping refer to the depth of coverage used in the paper, and higher depth may allow 
a better overlap of gDNA and cfDNA. In none of the cases cfDNA genotyping identified additional somatic 
mutations not detected in the purified BM PCs, thus suggesting that, as far as our limited patient cohort is 
concerned, the genotype of PC collected from a single tumor site is already representative of the entire 
tumor genetics. Alternatively, spatial genomic heterogeneity, supported by very recent findings in MM,14 may 
exist but involving minor subclones not sufficiently represented to be detectable in plasma. 
Our results provide the proof of principle that circulating tumor cfDNA genotyping is a feasible, non-
invasive, real-time approach that reliably detects clonal and subclonal somatic mutations represented in at 
least 5% of alleles in tumor PCs. Despite the genetic heterogeneity characterizing MM, and the inclusion in 
the study cohort of seven patients at pre-malignant/asymptomatic disease stages, the designed gene-panel 
employed in our study proved to be very effective, in that it allowed the recovery of at least one mutation in 
tumor gDNA of 20/28 (71%) cases. To the best of our knowledge, this is the first gene panel specifically 
created to maximize mutational recovery in MM patients by using an affordable number of genes, and by 
virtue of this potentially effective and manageable even in clinical practice in a hopefully near future. 
One of the original findings of the study is that cfDNA genotyping can resolve tumor genetics also in 
cases at early disease stages as SMM patients, who may benefit the most from this non-invasive approach. 
Indeed, among asymptomatic patients cfDNA genotyping could allow a non-invasive longitudinal molecular 
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monitoring of clonal evolution and the identification of the switch point on which the disease acquires high-
risk genetic features. This has been prevented so far by the unfeasibility of serial BM sampling in the clinical 
routine. 
An immediate clinical application of cfDNA genotyping in MM could be the incorporation of this 
minimally-invasive method in clinical trials for the identification of patients carrying actionable mutations and 
their longitudinal genetic monitoring during targeted therapy administration or for the estimation of minimal 
residual disease.  
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Table 1A. Somatic non-synonymous mutations discovered by cfDNA genotyping and their validation in tumor gDNA 
ID 
Sample Gene CHR 
Absolute 
position* REF VAR 
cDNA 
change§ Protein change 
cfDNA 
allele fraction 
gDNA 
allele fraction 
ID1 CYLD chr16 50820803 A T c.1987A>T p.R663W 0.95% 26.75% 
ID2 KRAS chr12 25380276 T A c.182A>T p.Q61L 25.01% 44.72% 
ID3 NRAS chr1 115258747 C A c.35G>T p.G12V 3.08% 63.07% 
ID5 KRAS chr12 25380279 C T c.179G>A p.G60D 1.05% 15.42% 
ID7 FAM46C chr1 118166229 T C c.739T>C p.Y247H 3.82% 53.38% 
ID7 NRAS chr1 115256529 T C c.182A>G p.Q61R 6.72% 54.57% 
ID7 TRAF3 chr14 103363617 A - c.839_839delA p.E280fs*3 9.66% 76.97% 
ID8 CYLD chr16 50813911 G A c.1474G>A p.G492S 0.87% 3.93% 
ID11 KRAS chr12 25398281 C T c.38G>A p.G13D 4.39% 16.82% 
ID12 NRAS chr1 115256529 T C c.182A>G p.Q61R 3.33% 35.14% 
ID13 NRAS chr1 115256530 G T c.181C>A p.Q61K 32.52% 19.11% 
ID15 DIS3 chr13 73337723 C T c.1993G>A p.E665K 37.86% 86.29% 
ID15 TP53 chr17 7578269 G A c.580C>T P.L194F 36.29% 81.79% 
ID17 TP53 chr17 7577610 T A c.673-2A>T p.224? 8.84% 79.53% 
ID18 IRF4 chr6 394920 G T c.316G>T p.D106Y 1.48% 39.08% 
ID18 TRAF3 chr14 103336686 A G c.148A>G p.K50E 0.29% 4.86% 
ID19 FAM46C chr1 118165764 G C c.274G>C p.D92H 0.68% 6.98% 
ID19 NRAS chr1 115256521 A C c.190T>G p.Y64D 0.65% 9.97% 
ID21 NRAS chr1 115256529 T G c.182A>C p.Q61P 0.54% 26.06% 
ID21 TP53 chr17 7578406 C T c.524G>A p.R175H 0.73% 38.91% 
ID26 FAM46C chr1 118165699 G C c.209G>C p.R70P 1.22% 5.16% 
ID26 FAM46C chr1 118166036 C G c.546C>G p.D182E 5.35% 18.83% 
ID26 NRAS chr1 115256529 T C c.182A>G p.Q61R 16.08% 32.59% 
ID26 NRAS chr1 115256530 G T c.181C>A p.Q61K 11.55% 15.04% 
ID27 DIS3 chr13 73337723 C T c.1993G>A p.E665K 0.64% 51.36% 
ID27 TRAF3 chr14 103363719 C T c.941C>T p.S314F 0.42% 33.81% 
ID28 BRAF chr7 140453136 A T c.1799T>A p.V600E 1.43% 32.88% 
ID29 KRAS chr12 25398281 C T c.38G>A p.G13D 11.36% 43.4% 
 
Table 1B. Somatic non-synonymous mutations discovered in tumor gDNA genotyping and missed in plasma cfDNA 
ID 
Sample Gene CHR 
Absolute 
position* REF VAR 
cDNA 
change§ Protein change 
cfDNA 
allele fraction 
gDNA 
allele fraction 
ID3 TP53 chr17 7577570 C T c.711G>A p.M237I - 3.31% 
ID3 TP53 chr17 7577121 G A c.817C>T p.R273C - 1.83% 
ID6 CYLD chr16 50785530 C T c.520C>T p.174Q* - 2.44% 
ID8 CYLD chr16 50785572 C T c.562C>T p.188Q* - 4.88% 
ID8 KRAS chr12 25380275 T A c.183A>T p.Q61H - 1.14% 
ID8 NRAS chr1 115256530 G T c.181C>A p.Q61K - 2.55% 
ID14 CYLD chr16 50828193 G A c.2540G>A p.W847* - 4.96% 
ID18 SP140 chr2 231176307 C A c.2502C>A p.Y834* - 2.43% 
ID18 ZNF462 chr9 109686963 G T c.770G>T p.R257L - 3.5% 
ID19 KRAS chr12 25398285 C T c.34G>A p.G12S - 1.46% 
ID19 NRAS chr1 115258747 C G c.35G>C p.G12A - 3.58% 
Abbreviations: CHR, chromosome; REF, reference allele; VAR, variant allele. 
*Absolute chromosome coordinates of each variant based on the hg19 version of the human genome assembly. 
§cDNA change determined on the following RefSeq: NM_015247.2 for CYLD, NM_033360.3 for KRAS, NM_002524.4 for NRAS, 
NM_017709.3 for FAM46C, NM_003300.3 for TRAF3, NM_014953.3 for DIS3, NM_000546.5 for TP53, NM_002460.3 for IRF4, 
NM_004333.4 for BRAF, NM_007237.4 for SP140, NM_021224.4 for ZNF462. 
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FIGURE LEGEND 
Figure 1. Overview of the mutations identified in the PC dyscrasia series. (A) Mutations detected in plasma 
cfDNA and confirmed in tumor gDNA are filled in red; mutations detected in tumor gDNA only are filled in 
blue. Each column represents one tumor sample and each row represents one gene. The fraction of tumors 
with mutations in each gene is plotted (right). The number and the type of mutations in a given tumor are 
plotted above the heat map. Patients positive for del(17p) are framed in black. (B) Bar graph of the allele 
frequencies in tumor gDNA of the variants that were discovered in plasma cfDNA (red bars) or missed in 
plasma cfDNA (blue bars). The dashed line tracks the 5% allelic frequency threshold. 
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Supplementary Methods 
 
Patients 
The study had a prospective, observational, nonintervention design and consisted in the collection of peripheral blood (PB) 
samples and clinical data from plasma cell (PC) dyscrasia patients. Inclusion criteria were: (1) male or female adults >18 
years old; (2) diagnosis of multiple myeloma (MM) or monoclonal gammopathy of undetermined significance (MGUS) after 
pathological revision; (3) evidence of signed informed consent. A total of 28 patients fulfilled the inclusion criteria and were 
recruited for the study from September 2016 to May 2017 (Supplementary Table S1). The following biological material was 
collected: (1) cfDNA isolated from plasma, (2) tumor genomic DNA (gDNA) from the CD138+ purified PCs from BM 
aspiration, for comparative purposes, and (3) normal germline gDNA extracted from peripheral blood (PB) granulocytes 
after Ficoll separation. Patients provided informed consent in accordance with local institutional review board requirements 
and the Declaration of Helsinki. 
 
Isolation and analysis of plasma cfDNA 
PB (20 ml maximum) was collected in Cell-Free DNA BCT tubes that allow obtaining stable cfDNA samples while preventing 
gDNA contamination that may occur due to nucleated cell disruption during sample storage, thus avoiding pre-analytical 
issues affecting cfDNA genotyping. PB was centrifuged at 820 g for 10 min to separate plasma from cells. Plasma was then 
further centrifuged at 20000 g for 10 min to pellet and remove any remaining cells and stored at -80°C until DNA extraction. 
cfDNA was extracted from 1-3 ml aliquots of plasma (to allow the recovery of enough genomic equivalents of DNA to reach 
a genotyping sensitivity of 10-3) using the QIAamp circulating nucleic acid kit (Qiagen) and quantized using Quant-iT™ 
PicoGreen dsDNA Assay kit (ThermoFisher Scientific). Contamination of plasma cfDNA from gDNA released by blood 
nucleated cell disruption was ruled out by checking, through the Bioanalyzer (Agilent Technologies) instrument, the size of 
the DNA extracted from plasma. 
 
gDNA extraction 
PB granulocytes were separated by Ficoll gradient density centrifugation as a source of normal germline gDNA. Tumor 
gDNA was isolated from PCs puriﬁed using CD138 immunomagnetic microbeads as previously described 1, 2 (CD138+ cell 
percentage was ≥90% in all cases). gDNA was extracted according to standard procedures. 
 
Library design for hybrid selection 
A targeted resequencing gene panel, including coding exons and splice sites of 14 genes that are recurrently mutated in 
MM patients, was specifically designed for this project (target region: 30989bp: BRAF, CCND1, CYLD, DIS3, EGR1, 
FAM46C, IRF4, KRAS, NRAS, PRDM1, SP140, TP53, TRAF3, ZNF462; Supplementary Table S2). Inclusion criteria of 
gene panel design were based on publicly available sequencing data from three distinct datasets 3-5 and were as follows: 
(i) genes that were recurrently mutated in ≥ 3% of MM tumors; (ii) genes that were cross-validated in at least two of the 
considered genomic datasets. An in silico validation of the designed gene panel in the three aforementioned patients cohorts 
resulted in the recovery of at least one clonal mutation in 68% (95% confidence interval [CI]: 58 to 76) of MM cases. 
 
CAPP-seq library preparation and ultra-deep NGS 
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The gene panel was analyzed in plasma cfDNA, and for comparative purposes to filter out polymorphisms, in normal gDNA 
from the paired granulocytes as source of germline material. The gDNA from the paired CD138+ purified plasma cells from 
BM aspiration was also investigated in the same cases to assess the accuracy of plasma cfDNA genotyping. Tumor and 
germline gDNA (median 400 ng) were sheared through sonication before library construction to obtain 200-bp fragments. 
Plasma cfDNA, which is naturally fragmented, was used (average: 59 ng; median: 48 ng; range: 0.05-400 ng) for library 
construction without additional fragmentation. Targeted ultra-deep-next generation sequencing was performed on plasma 
cfDNA, tumor and germline gDNA by using the CAPP-seq approach, which has been validated for plasma cfDNA genotyping 
6. The NGS libraries were constructed using the KAPA Library Preparation Kit (Kapa Biosystems) and hybrid selection was 
performed with the custom SeqCap EZ Choice Library (Roche NimbleGen). The manufacturer's protocols were modified as 
previously reported 6. Multiplexed libraries were sequenced using 300-bp paired-end runs on an Illumina MiSeq sequencer. 
Each run included 24 multiplexed samples in order to allow >2000x coverage in >80% of the target region. 
 
Bioinformatic pipeline for variant calling 
Mutation calling in plasma cfDNA was performed separately and in blind from mutation calling in tumor gDNA from purified 
PCs. We deduped FASTQ sequencing reads by utilizing FastUniq v1.1. The deduped FASTQ sequencing reads were locally 
aligned to the hg19 version of the human genome using BWA v.0.6.2, and sorted, indexed and assembled into a mpileup 
file using SAMtools v.1. The aligned reads were processed with mpileup. Single nucleotide variations and indels were called 
in plasma cfDNA vs normal gDNA, and tumor gDNA vs normal gDNA, respectively, by using the somatic function of 
VarScan2 (a minimum Phred quality score of 30 was imposed). The variant called by VarScan 2 were annotated by using 
SeattleSeq Annotation 138. Variants annotated as SNPs, intronic variants mapping >2 bp before the start or after the end 
of coding exons, and synonymous variants were filtered out. To filter out variants below the base-pair resolution background 
frequencies, the Fisher's exact test was used to test whether the variant frequency called by VarScan 2 in cfDNA or tumor 
gDNA, respectively, was significantly higher from that called in the corresponding paired germline gDNA, after adjusting for 
multiple comparison by Bonferroni test (Bonferroni-adjusted P=4.03252e-7). To further filter out systemic sequencing errors, 
a database containing all background allele frequencies in all the specimens analyzed was assembled. Based on the 
assumption that all background allele fractions follow a normal distribution, a Z-test was employed to test whether a given 
variant differs significantly in its frequency from typical DNA background at the same position in all the other DNA samples, 
after adjusting for multiple comparison by Bonferroni. Variants that did not pass this filter were not further considered. Variant 
allele frequencies for the resulting candidate mutations and the background error rate were visualized using IGV (see 
Supplementary Figure S5 for a representative example). 
 
Statistical analysis 
The sensitivity and specificity of plasma cfDNA genotyping were calculated in comparison with tumor gDNA genotyping as 
the gold standard. The analysis were performed with the Statistical Package for the Social Sciences (SPSS) software 
(Chicago, IL) and with R statistical package (http://www.r-project.org).
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Supplementary Table S1. Patients’ characteristics 
ID Age Gender Diagnosis Phase 
% of PCs in 
BM biopsy 
Monoclonal 
component 
FLC ratio 
ISS 
stage 
del(13q) del(17p) t(4;14) t(14;16) t(11;14) HD 1p loss 1q gain 
1 46 F MM ND 50 Micromolecular λ λ/κ FLC = 753 3 neg neg neg neg pos neg neg neg 
2 52 M MM ND 90 IgGκ κ/λ FLC = 708 3 pos neg neg neg neg pos neg pos 
3 70 M MM ND 30 IgGκ κ/λ FLC = 104 1 neg pos neg neg neg pos neg neg 
4 53 M MM RR 25 IgAκ κ/λ FLC = 3 2 n.d. n.d. n.d. n.d. n.d. pos neg pos 
5 56 M MM ND 80 IgGκ κ/λ FLC = 36 3 neg neg neg neg neg neg pos pos 
6 66 M MM ND 28 IgAλ λ/κ FLC = 182 1 neg neg neg neg neg pos neg pos 
7 46 F MM RR 30 Micromolecular λ λ/κ FLC > 27000 1 pos neg neg neg neg pos neg pos 
8 52 F MM ND 45 Micromolecular λ λ/κ FLC = 446 1 pos neg neg neg neg pos neg pos 
9 76 M sMM ND 55 IgGκ κ/λ FLC = 4 n.a. neg neg neg neg neg pos neg pos 
10 76 F MM ND 30 IgAλ λ/κ FLC = 6 1 n.d. neg neg neg neg neg neg pos 
11 54 M MM ND 40 IgAκ κ/λ FLC = 19 2 pos neg neg neg neg pos neg neg 
12 77 M MM ND 30 IgGκ κ/λ FLC = 17 2 neg neg neg neg neg pos neg neg 
13 64 M MM ND 60 IgAλ λ/κ FLC = 210 3 n.d. neg neg neg neg neg neg pos 
14 61 F sMM ND 55 IgGκ κ/λ FLC = 29 n.a. pos neg neg neg neg pos neg neg 
15 68 M MM ND 70 IgAλ λ/κ FLC = 65 3 pos pos pos neg neg neg neg pos 
16 76 F sMM ND 18 IgGκ κ/λ FLC = 44 n.a. n.d. neg neg neg neg pos neg neg 
17 59 M MM ND 90 Micromolecular λ λ/κ FLC = 129 3 pos pos neg neg pos pos pos neg 
18 68 F MM ND 40 IgGλ λ/κ FLC = 338 1 n.d. neg neg neg neg neg neg pos 
19 64 F MM RR 65 IgGκ κ/λ FLC = 15 2 neg neg neg neg pos neg neg neg 
20 82 F MM ND 11 IgGκ κ/λ FLC = 21 1 n.d. neg neg neg pos neg neg neg 
21 59 F sMM ND 10 IgGλ λ/κ FLC = 5 n.a. n.d. neg neg neg pos neg neg neg 
22 78 M MGUS ND 8 IgMκ κ/λ FLC = 3 n.a. neg neg neg neg pos neg neg neg 
26 47 F MM ND 50 IgAλ λ/κ FLC = 6 1 n.d. neg neg neg neg neg neg neg 
27 71 M MM ND 28 IgGκ κ/λ FLC = 109 1 n.d. neg neg neg neg neg neg pos 
28 68 M sMM ND 38 IgAλ λ/κ FLC = 23 n.a. n.d. neg neg neg neg pos neg neg 
29 69 M MM ND 70 IgGκ κ/λ FLC = 200 2 n.d. neg neg neg neg neg neg pos 
30 50 F MM ND 60 IgAκ κ/λ FLC = 108 1 n.d. neg neg neg neg neg neg neg 
31 61 F MGUS ND 7 IgGκ κ/λ FLC = 4 n.a. neg neg neg neg neg pos neg neg 
Abbreviations: F, female; M, male; MM, multiple myeloma; sMM, smoldering multiple myeloma; MGUS, monoclonal gammopathy of undetermined significance; ND, newly diagnosed; 
RR, relapsed/refractory; BM, bone marrow; FLC, free light-chain; ISS, International Staging System; n.a., not applicable; n.d., not determined; HD, hyperdiploidy.
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Supplementary Table S2. Target region 
Gene chromosome coding exon start plus splice site (2bp) coding exon stop plus splice site (2bp) 
NRAS chr1 
115251156 115251277 
115252188 115252351 
115256419 115256601 
115258669 115258783 
    
FAM46C chr1 118165491 118166666 
    
CCND1 chr11 
69456082 69456281 
69457797 69458016 
69458598 69458761 
69462760 69462912 
69465884 69466050 
    
KRAS chr12 
25368375 25368496 
25378546 25378709 
25380166 25380348 
25398206 25398318 
    
DIS3 chr13 
73333933 73334018 
73334665 73334791 
73335499 73335661 
73335782 73335954 
73336059 73336277 
73337587 73337747 
73340108 73340198 
73342921 73343052 
73345040 73345128 
73345217 73345285 
73345931 73346036 
73346295 73346415 
73346829 73346979 
73347820 73347961 
73348082 73348199 
73349347 73349515 
73350061 73350232 
73351556 73351633 
73352323 73352520 
73354982 73355143 
73355741 73355970 
    
TRAF3 chr14 
103336537 103336785 
103338252 103338307 
103341959 103342067 
103342693 103342864 
103352524 103352608 
103355895 103355973 
103357660 103357756 
103363596 103363740 
103369590 103369768 
103371548 103372121 
    
CYLD chr16 
50783610 50784115 
50785513 50785819 
50788228 50788337 
50810088 50810190 
50811734 50811854 
50813574 50813957 
50815155 50815324 
50816234 50816379 
50818238 50818364 
50820764 50820859 
50821695 50821765 
50825467 50825603 
50826506 50826618 
50827455 50827577 
50828121 50828341 
50830233 50830419 
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Supplementary Table S2. (continued) 
Gene chromosome coding exon start plus splice site (2bp) coding exon stop plus splice site (2bp) 
TP53 chr17 
7572927 7573010 
7573925 7574035 
7576851 7576928 
7577017 7577157 
7577497 7577610 
7578175 7578291 
7578369 7578556 
7579310 7579592 
7579698 7579723 
7579837 7579912 
    
SP140 chr2 
231090560 231090620 
231101796 231101977 
231102926 231103098 
231106117 231106204 
231108444 231108528 
231109701 231109797 
231110576 231110657 
231112629 231112782 
231113598 231113685 
231115694 231115778 
231118029 231118134 
231120165 231120249 
231134245 231134335 
231134550 231134670 
231135299 231135356 
231149059 231149128 
231150465 231150549 
231152605 231152683 
231155173 231155281 
231157359 231157505 
231158984 231159035 
231162134 231162179 
231174637 231174756 
231175456 231175568 
231175867 231175948 
231176165 231176312 
231177299 231177399 
    
EGR1 chr5 137801451 137801759 
137802444 137803770 
    
IRF4 chr6 
393153 393370 
394819 395009 
395845 395937 
397106 397254 
398826 398937 
401422 401779 
405016 405132 
407453 407598 
    
PRDM1 chr6 
106534429 106534472 
106536074 106536326 
106543488 106543611 
106547173 106547429 
106552698 106553810 
106554244 106554376 
106554784 106555361 
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Supplementary Table S2. (continued) 
Gene chromosome coding exon start plus splice site (2bp) coding exon stop plus splice site (2bp) 
BRAF chr7 
140434397 140434572 
140439610 140439748 
140449085 140449220 
140453073 140453195 
140453985 140454035 
140476710 140476890 
140477789 140477877 
140481374 140481495 
140482819 140482959 
140487346 140487386 
140494106 140494269 
140500160 140500283 
140501210 140501362 
140507758 140507864 
140508690 140508797 
140534407 140534674 
140549909 140550014 
140624364 140624503 
    
ZNF462 chr9 
109685665 109685886 
109686412 109692042 
109692804 109692972 
109694725 109694832 
109697782 109697904 
109701195 109701390 
109734284 109734555 
109736416 109736556 
109746465 109746692 
109765573 109765709 
109771824 109771951 
109773102 109773311 
Absolute chromosome coordinates are based on the hg19 version of the human genome assembly.
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Supplementary Table S3. Percentage of target region 
covered ≥1000X and ≥2000X in distinct patient samples. 
ID Sample 
Target Region Coverage (%) 
≥ 1000X ≥ 2000X 
ID1 
GL 100.0 99.5 
PCS 99.6 98.3 
PL 99.4 97.9 
ID2 
GL 99.5 99.5 
PCS 99.4 96.9 
PL 97.8 83.5 
ID3 
GL 98.7 85.9 
PCS 99.9 99.5 
PL 98.9 95.8 
ID4 
GL 98.3 43.0 
PCS 100.0 100.0 
PL 97.6 58.5 
ID5 
GL 97.7 63.4 
PCS 100.0 99.6 
PL 98.2 93.3 
ID6 
GL 100.0 99.5 
PCS 99.5 99.5 
PL 99.4 97.4 
ID7 
GL 99.6 99.5 
PCS 99.6 98.8 
PL 99.5 97.9 
ID8 
GL 99.5 98.6 
PCS 99.5 99.5 
PL 98.6 91.9 
ID9 
GL 99.5 98.8 
PCS 99.5 98.9 
PL 99.4 97.8 
ID10 
GL 99.5 99.0 
PCS 99.3 96.9 
PL 99.5 98.5 
ID11 
GL 99.5 98.7 
PCS 99.5 99.3 
PL 99.3 95.5 
ID12 
GL 99.5 99.0 
PCS 99.5 99.1 
PL 94.5 21.9 
ID13 
GL 99.5 98.9 
PCS 99.5 98.7 
PL 98.7 86.0 
ID14 
GL 99.5 98.8 
PCS 99.6 98.8 
PL 99.4 96.5 
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Supplementary Table S3. (continued) 
ID Sample 
Target Region Coverage (%) 
≥ 1000X ≥ 2000X 
ID15 
GL 99.5 98.7 
PCS 99.5 98.6 
PL 99.4 98.0 
ID16 
GL 99.5 98.9 
PCS 99.5 98.3 
PL 97.3 62.8 
ID17 
GL 98.6 97.5 
PCS 99.5 95.2 
PL 98.5 97.0 
ID18 
GL 98.7 96.3 
PCS 94.7 84.0 
PL 98.7 97.8 
ID19 
GL 98.4 92.0 
PCS 96.4 74.9 
PL 98.7 97.5 
ID20 
GL 98.6 96.5 
PCS 97.7 95.2 
PL 98.7 96.8 
ID21 
GL 98.5 94.9 
PCS 98.0 94.9 
PL 98.6 96.7 
ID22 
GL 98.7 97.5 
PCS 98.7 97.8 
PL 98.7 96.5 
ID26 
GL 98.9 98.2 
PCS 99.5 99.5 
PL 99.4 97.1 
ID27 
GL 99.5 99.0 
PCS 99.5 98.8 
PL 99.5 98.8 
ID28 
GL 99.5 99.0 
PCS 99.5 99.5 
PL 98.7 90.3 
ID29 
GL 98.2 94.5 
PCS 99.6 99.5 
PL 99.6 99.4 
ID30 
GL 99.5 98.9 
PCS 100.0 99.5 
PL 99.5 98.1 
ID31 
GL 99.6 98.9 
PCS 99.6 98.9 
PL 99.4 98.3 
Abbreviations: GL, normal germline DNA from granulocytes; 
PCS, tumor genomic DNA from plasma cells; PL, cfDNA from 
plasma. 
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Supplementary Figure S1. (A) Correlation between cfDNA amount and bone marrow plasma cell infiltration. 
(B) cfDNA amount according to diagnosis/risk stratification: the levels of cfDNA are significantly higher in MM 
patients at ISS stage 3 compared with MGUS/SMM samples and MM cases at ISS stages 1-2 (P=0.01; Mann-
Whitney test).
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Supplementary Figure S2. Coverage across the target region. Depth of coverage (y axis) across the target 
region (x axis) by CAPP-seq of (A) gDNA from the germline (granulocytes) samples, (B) tumor gDNA from bone 
marrow plasma cells, and (C) plasma cfDNA. Each dot represents the sequencing depth on that specific position 
of the target region of one single individual sample. The solid blue line shows the median depth of coverage, 
while the dash blue lines show the interquartile range. The dashed red line shows the 2000X coverage.
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Supplementary Figure S3. Prevalence and molecular spectrum of nonsynonymous somatic mutations discovered in plasma cfDNA. The most 
mutated genes are reported: (A) KRAS gene and (B) NRAS gene. The molecular spectrum of nonsynonymous somatic mutations identified in plasma 
cfDNA (in the upper part of the figure) compared with the molecular spectrum of nonsynonymous somatic mutations that have been detected in the 
tumor gDNA in published MM series and reported in the COSMIC database (version 81) 7 (in the lower part of the figure). Mutation maps were obtained 
through Mutation Mapper version 1.0.1. Color codes indicate the type of the mutations: truncating mutations include nonsense, frameshift deletion, 
frameshift insertion, splice site.
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Supplementary Figure S4. Concordance between plasma cfDNA and tumor gDNA genotyping. (A) The fraction of tumor biopsy–confirmed mutations 
that were detected in plasma is shown. Patients are ordered by decreasing detection rates. The red portion of the bars indicates the prevalence of 
tumor biopsy–confirmed mutations that were detected in plasma cfDNA. The gray portion of the bars indicates the prevalence of tumor biopsy-
confirmed mutations that were not detected in plasma cfDNA. (B) The mutation abundance in plasma cfDNA vs the mutation abundance in tumor 
gDNA is comparatively represented in the scatter plot for each identified variant. (C) ROC analysis illustrating the performance of gDNA genotyping 
in discriminating the ability of cfDNA genotyping to detect biopsy-confirmed mutations according to the variant allele frequency of mutations in tumor 
gDNA.
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Supplementary Figure S5. Visualization of deep sequencing data in BM gDNA (A) and cfDNA (B) of patient 
ID26 by Integrated Genome Viewer software. Two adjacent base substitutions affecting the same codon and 
originating distinct NRAS p.Q61R and p.Q61K mutations are shown. The lack of sequencing reads carrying both 
mutations suggested that these two substitutions likely involved different tumor subclones. Reads were sorted 
by base at chr1:115,256,529 locus and then again sorted by base at chr1:115,256,530 locus. Red bars show 
G>T substitutions at the chr1:115,256,530 locus. Blue bars show T>C substitution at the chr1:115,256,529 locus. 
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